Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim

Jeungwoon Hong, Byoungju Lee, Kwanyub Kang, Seung Hoon Lee, Jaehwan Ryu, Gangsoo Jung, Jaetaek Oh, Eui Cheol Jo, Chan Wha Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We describe the characterisation of a novel monoPEGylated recombinant human granulocyte colony-stimulating factor analogue, pegteograstim (Neulapeg), prepared by site-specific 20 kDa maleimide-PEG conjugation. An additional cysteine was inserted between Gly136 and Ala137 of filgrastim (methionyl human granulocyte colony-stimulating factor) for site-specific PEGylation, and Cys18 of filgrastim was replaced with Ser18 to prevent unwanted PEGylation. Pegteograstim was produced by Escherichia coli and purified by cation exchange chromatography, and its structural, physicochemical, biological and immunological properties were investigated. Male Sprague-Dawley rats were administered pegteograstim (100 μg/kg) and the pharmacokinetics and pharmacodynamics compared with those of filgrastim. The results of long-term stability testing of pegteograstim revealed no significant change in its quality attributes at 2–8 °C for 36 months. In addition, pegteograstim was stable under the accelerated conditions (25 ± 2 °C, RH of 60 ± 5%) for 6 months. The site-specific monoPEGylated pegteograstim is a highly pure, stable and novel drug for long-lasting treatment of chemotherapy-induced neutropenia.

Original languageEnglish
Pages (from-to)54-61
Number of pages8
JournalBiologicals
Volume51
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Pharmacodynamics
Pharmacokinetics
Chemotherapy
Chromatography
Escherichia coli
Polyethylene glycols
Rats
Ion exchange
Positive ions
Granulocyte Colony-Stimulating Factor
Testing
Neutropenia
Cysteine
Sprague Dawley Rats
Cations
Drug Therapy
Pharmaceutical Preparations
Filgrastim
Therapeutics

Keywords

  • Filgrastim
  • Maleimide-PEG
  • Neutropenia
  • Pegteograstim
  • PEGylation
  • rhG-CSF analogue

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Immunology and Microbiology(all)
  • Pharmacology

Cite this

Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim. / Hong, Jeungwoon; Lee, Byoungju; Kang, Kwanyub; Lee, Seung Hoon; Ryu, Jaehwan; Jung, Gangsoo; Oh, Jaetaek; Jo, Eui Cheol; Kim, Chan Wha.

In: Biologicals, Vol. 51, 01.01.2018, p. 54-61.

Research output: Contribution to journalArticle

Hong, Jeungwoon ; Lee, Byoungju ; Kang, Kwanyub ; Lee, Seung Hoon ; Ryu, Jaehwan ; Jung, Gangsoo ; Oh, Jaetaek ; Jo, Eui Cheol ; Kim, Chan Wha. / Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim. In: Biologicals. 2018 ; Vol. 51. pp. 54-61.
@article{00283619dc5e4e649f764190c12b9d39,
title = "Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim",
abstract = "We describe the characterisation of a novel monoPEGylated recombinant human granulocyte colony-stimulating factor analogue, pegteograstim (Neulapeg), prepared by site-specific 20 kDa maleimide-PEG conjugation. An additional cysteine was inserted between Gly136 and Ala137 of filgrastim (methionyl human granulocyte colony-stimulating factor) for site-specific PEGylation, and Cys18 of filgrastim was replaced with Ser18 to prevent unwanted PEGylation. Pegteograstim was produced by Escherichia coli and purified by cation exchange chromatography, and its structural, physicochemical, biological and immunological properties were investigated. Male Sprague-Dawley rats were administered pegteograstim (100 μg/kg) and the pharmacokinetics and pharmacodynamics compared with those of filgrastim. The results of long-term stability testing of pegteograstim revealed no significant change in its quality attributes at 2–8 °C for 36 months. In addition, pegteograstim was stable under the accelerated conditions (25 ± 2 °C, RH of 60 ± 5{\%}) for 6 months. The site-specific monoPEGylated pegteograstim is a highly pure, stable and novel drug for long-lasting treatment of chemotherapy-induced neutropenia.",
keywords = "Filgrastim, Maleimide-PEG, Neutropenia, Pegteograstim, PEGylation, rhG-CSF analogue",
author = "Jeungwoon Hong and Byoungju Lee and Kwanyub Kang and Lee, {Seung Hoon} and Jaehwan Ryu and Gangsoo Jung and Jaetaek Oh and Jo, {Eui Cheol} and Kim, {Chan Wha}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.biologicals.2017.10.002",
language = "English",
volume = "51",
pages = "54--61",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim

AU - Hong, Jeungwoon

AU - Lee, Byoungju

AU - Kang, Kwanyub

AU - Lee, Seung Hoon

AU - Ryu, Jaehwan

AU - Jung, Gangsoo

AU - Oh, Jaetaek

AU - Jo, Eui Cheol

AU - Kim, Chan Wha

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We describe the characterisation of a novel monoPEGylated recombinant human granulocyte colony-stimulating factor analogue, pegteograstim (Neulapeg), prepared by site-specific 20 kDa maleimide-PEG conjugation. An additional cysteine was inserted between Gly136 and Ala137 of filgrastim (methionyl human granulocyte colony-stimulating factor) for site-specific PEGylation, and Cys18 of filgrastim was replaced with Ser18 to prevent unwanted PEGylation. Pegteograstim was produced by Escherichia coli and purified by cation exchange chromatography, and its structural, physicochemical, biological and immunological properties were investigated. Male Sprague-Dawley rats were administered pegteograstim (100 μg/kg) and the pharmacokinetics and pharmacodynamics compared with those of filgrastim. The results of long-term stability testing of pegteograstim revealed no significant change in its quality attributes at 2–8 °C for 36 months. In addition, pegteograstim was stable under the accelerated conditions (25 ± 2 °C, RH of 60 ± 5%) for 6 months. The site-specific monoPEGylated pegteograstim is a highly pure, stable and novel drug for long-lasting treatment of chemotherapy-induced neutropenia.

AB - We describe the characterisation of a novel monoPEGylated recombinant human granulocyte colony-stimulating factor analogue, pegteograstim (Neulapeg), prepared by site-specific 20 kDa maleimide-PEG conjugation. An additional cysteine was inserted between Gly136 and Ala137 of filgrastim (methionyl human granulocyte colony-stimulating factor) for site-specific PEGylation, and Cys18 of filgrastim was replaced with Ser18 to prevent unwanted PEGylation. Pegteograstim was produced by Escherichia coli and purified by cation exchange chromatography, and its structural, physicochemical, biological and immunological properties were investigated. Male Sprague-Dawley rats were administered pegteograstim (100 μg/kg) and the pharmacokinetics and pharmacodynamics compared with those of filgrastim. The results of long-term stability testing of pegteograstim revealed no significant change in its quality attributes at 2–8 °C for 36 months. In addition, pegteograstim was stable under the accelerated conditions (25 ± 2 °C, RH of 60 ± 5%) for 6 months. The site-specific monoPEGylated pegteograstim is a highly pure, stable and novel drug for long-lasting treatment of chemotherapy-induced neutropenia.

KW - Filgrastim

KW - Maleimide-PEG

KW - Neutropenia

KW - Pegteograstim

KW - PEGylation

KW - rhG-CSF analogue

UR - http://www.scopus.com/inward/record.url?scp=85061560916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061560916&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2017.10.002

DO - 10.1016/j.biologicals.2017.10.002

M3 - Article

C2 - 29107446

AN - SCOPUS:85061560916

VL - 51

SP - 54

EP - 61

JO - Biologicals

JF - Biologicals

SN - 1045-1056

ER -